Brielle Benyon

When it came to content on the mental health effects of prostate cancer, a review of YouTube videos found the results to be lacking.

Patients with stage non-small cell lung cancer tended to have better outcomes when Opdivo was added to their pre-surgical chemotherapy treatment.

Patients with cancer undergoing immunotherapy treatment did not have increased hospitalizations or serious side effects after getting the flu shot.

Taking five or more medications increased the risk of death, hospitalizations and ER visits in elderly patients with colorectal cancer.

A chemotherapy shortage is resulting in altered treatment plans for many patients with cancer. CURE® spoke with experts about what that means for patients — and what they can do about it.

Patients with depression or anxiety at the time of a diffuse large B-cell lymphoma diagnosis tended to have worse survival, recent research showed.

Being overweight might improve overall survival and progression-free survival for patients with head and neck cancer undergoing chemoradiotherapy, recent research showed.

Recent research found that patients who supplemented their vitamin D intake tended to have improved colorectal cancer outcomes.

An expert gives an overview of the treatment options for uveal melanoma, and why he considers hope to be an essential part of the care plan.

Singer-songwriter Andrew McMahon is not the same person he was before his leukemia diagnosis, and that’s OK, he said.

The addition of Tecentriq to Cabometyx did not improve the length of time patients lived without their disease getting worse for individuals with previously treated advanced kidney cancer, and came with additional side effects, too, recent research showed.

It is essential for patients to live a healthy lifestyle while undergoing treatment for multiple myeloma, an expert said.

The full approval is based on data showing that 80% of patients with B-ALL experienced a complete MRD response.

Adding Cabometyx to Opdivo and Yervoy tended to improve progression-free survival in patients with advanced kidney cancer, research showed.

We asked our audience what life hacks they learned to make cancer treatment a bit easier. Here’s what they had to say.

An expert discusses the ongoing SPARK trial for KRASG12-mutant non-small cell lung cancer, and what she hopes for the future of this patient population.

Here’s an overview of the new cancer regimens that gained Food and Drug Administration (FDA) approval in the spring of this year.

From Colin McFarlane and John Homme opening up about their cancer diagnoses to Pope Francis visiting a pediatric oncology ward, here’s what’s happening in the cancer space this week.

Watch Dr. Jerry Spivak, from Johns Hopkins University School of Medicine, discuss what is on the horizon in the management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Most patients with nonmetastatic castration-resistant prostate cancer were able to stay on their therapies long-term, research showed.

Watch Dr. Nikolai Podoltsev, from Yale School of Medicine, discuss the current management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

CAR-T cell therapies have not always been easy to access for patients with myeloma, though that is slowly changing, an expert explained.

A survey of cancer centers found that the majority of large centers are facing cisplatin and carboplatin shortages, and some are changing or delaying treatment because of it.

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

From Shannen Doherty’s announcement that her breast cancer spread to her brain to a nonprofit being established in memory of the late YouTuber, Technoblade, here’s what’s happening in the oncology space this week.

For patients with a history of cancer or who are genetically predisposed to it — as well as the general population — unintended weight loss may be the first sign of the disease, research showed.

Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.

Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.

Adding Opdivo and Yervoy to Cabometyx led to improved progression-free survival and disease control rates in patients with soft tissue sarcoma, recent research showed.

It may be more beneficial to reduce the dose of Verzenio rather than stop the drug altogether, according to the monarchE trial findings.